Iroko Cardio Global Sàrl announces observations on HDB dosing of tirofiban, abciximab in interventional cardiology
Posted in Drug Trial on September 4th, 2010Iroko Cardio Worldwide Sàrl announces long-term, three-year, mortality observations from the Configuration III, evident brand, multi-national swat comparing high-dose bolus (HDB) dosing of AGGRASTAT® (tirofiban) (25mcg/kg bolus followed especially a 0.15mcg/kg/min infusion as a service to 18-24 hours) vs. ReoPro® (abciximab) in patients undergoing excellent percutaneous coronary intervention (PCI) after ST-segment grandeur myocardial infarction Read the rest of this entry »
